Ibrutinib (CAS 936563-96-1)
See product citations (5)
Alternate Names:
Ibrutinib is also known as Imbruvica.
Application:
Ibrutinib is an irreversible Bruton′s tyrosine kinase inhibitor that selectively blocks B cell activation.
CAS Number:
936563-96-1
Molecular Weight:
440.5
Molecular Formula:
C25H24N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ibrutinib is a small molecule inhibitor that has become a focal point in biochemical research due to its ability to selectively target and inhibit Bruton′s tyrosine kinase (BTK). By binding covalently to the cysteine residue at the active site of BTK, Ibrutinib impedes the B-cell receptor signaling pathway, which is critical for B-cell development and function. This mechanism has made Ibrutinib a useful probe in immunology and cancer research, particularly in studying the signal transduction processes that underlie various B-cell malignancies and autoimmune disorders. Its role in these pathways provides researchers with a tool to dissect the complex biology of B-cell receptor signals and their contributions to disease progression at a molecular level. Furthermore, Ibrutinib is utilized in signal transduction research to understand the broader implications of kinase inhibition in cellular communication and function.
Ibrutinib (CAS 936563-96-1) References
- Ibrutinib: a new targeted therapy for hematologic cancers. | Smithson, CR. and Schneider, SM. 2015. Clin J Oncol Nurs. 19: E47-51. PMID: 26000590
- Targets for Ibrutinib Beyond B Cell Malignancies. | Berglöf, A., et al. 2015. Scand J Immunol. 82: 208-17. PMID: 26111359
- Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. | Nam, HY., et al. 2018. J Neuroinflammation. 15: 271. PMID: 30231870
- Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. | Gauthier, J., et al. 2020. Blood. 135: 1650-1660. PMID: 32076701
- Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation. | Huang, J., et al. 2021. Thromb Haemost. 121: 192-205. PMID: 32961571
- Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression. | Li, W., et al. 2021. Brain Behav Immun. 92: 10-24. PMID: 33181270
- Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases. | Guo, M., et al. 2021. Bioorg Med Chem Lett. 34: 127757. PMID: 33359446
- Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease. | Lee, HJ., et al. 2021. Aging Cell. 20: e13332. PMID: 33709472
- Ibrutinib ameliorates cerebral ischemia/reperfusion injury through autophagy activation and PI3K/Akt/mTOR signaling pathway in diabetic mice. | Jin, L., et al. 2021. Bioengineered. 12: 7432-7445. PMID: 34605340
- Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells. | Misek, SA., et al. 2022. Mol Pharmacol. 101: 1-12. PMID: 34732527
- Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. | Liu, J., et al. 2022. Pharmaceutics. 14: PMID: 36145624
- Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice. | Rao, H., et al. 2022. Int J Mol Sci. 23: PMID: 36362264
Inhibitor of:
1700008O03Rik, 2900062L11Rik, 3100002L24Rik, 3110052M02Rik, 4.1N, 4922501L14Rik, 4930408F14Rik, 4931406C07Rik, 5830411N06Rik, 7420461P10Rik, 9530053A07Rik, ABC1, AI987662, apoL11a, Arxes2, ASCL4, ATXN1L, B Cell Marker, B lymphocytes, Bcl-11a, Bcl-11b, Bcl-6b, Bcl-7b, Bcl11a, BEND4, BIGM103, BONO1, BTBD1, Btk, BTNL9, BXDC5, BZW1, C10orf47, C11orf49, C130050O18Rik, C1orf144, C1orf150, C1orf159, C1orf161, C1orf62, C2, C2orf47, C9orf103, CapZ-β, CARD11, CCDC150, CCDC82, CD200R4, CD22, CD300LD, CD32-C, CD45, CD79A, CD79B, cGKI, Cid, CLEC-9A, CS1, CSAGE, Cypt3, Dectin-2, DENND3, DKFZp761E198, DLD, DLST, DNAH14, DNB5, DNHL1, Doc 4, DOCK 10, DOCK 5, Dokl, DONSON, ELL2, EMR2, ENT1, Eos, Evx-1, FAM149A, FAM188B, FAM75D1, FCGR (Fc gamma receptor), FcRH3, FcRH4, FCRLM1, Fcrls, FHAD1, Fis1, FLJ13611, Fnk, Gads, Gight chain, GITRL, Gm1027, Gm3336, Gm3696, Gm4788, GRASP, HACS1, HELIC2, HEXIM2, hIws1, HOOK2, HRG-β3, HSFX2, HuB, HYPK, IFIT1, Ig κ, Ig κ chain, Ig λ, Ig λ chain, Ig λ chain V4A, Ig λ light chain, IgD, IgD Chain, IgD Chain C, IgG light chain, IgH, IgH-VJ558, IgHg, Igk-C, IgM, IL-27, IL-2R, ING4, IRF-4, JAM-C, Kar9, Kazrin, KCTD19, Lambda 5, LAT2, LAX1, ligatin, LIME, LIR-8, LNX4, LOC100040158, LOC100041061, LOC100041202, LOC100041214, LOC100041238, LOC100041244, LOC100041280, LOC100041319, LOC100041351, LOC100041356, LOC100041377, LOC100041385, LOC100041418, LOC100041434, LOC100041436, LOC100041448, LOC100041450, LOC100041458, LOC339047, LOC388237, LOC440330, LOC644477, LOC645282, LOC645733, LOC645851, LOC646237, LOC646823, LOC647176, LOC650947, LOC727862, LOC727992, LOC728256, LOC728581, LOC728694, LOC729001, LOC729104, LOC729174, LOC729460, LOC729504, LOC729847, LOC729854, LOC730111, LOC730151, LOC730205, LPLUNC4, LRRC30, LST1, LTK, Ly-49E, Ly6G6d, LZK, MAGE-D4B, MAML3, Mex3b, MFRP, MGA, MIC2, MLSN1, MORG1, MS4A4A, MSLNL, MTERF, MUM1, OC-3, OIP106, Olfr1354, Olfr209, Olfr547, Olfr549, Olr1029, Olr1059, Olr111, Olr1124, Olr1128, Olr1204, Olr1218, Olr1234, Olr1245, Olr1264, Olr129, Olr130, Olr1321, Olr1323, Olr1334, Olr1350, Olr1353, Olr1383, Olr1398, Olr1562, Olr1564, Olr159, Olr1642, Olr1657, Olr1704, Olr232, Olr233, Olr272, Olr309, Olr322, Olr348, Olr354, Olr363, Olr367, Olr374, Olr382, Olr390, Olr496, Olr515, Olr526, Olr530, Olr561, Olr575, Olr592, Olr598, Olr607, Olr608, Olr672, Olr697, Olr712, Olr714, Olr734, Olr749, Olr768, Olr775, Olr785, Olr791, Olr943, Olr962, Paired Box (PAX), PATE-N, Pax-5, PAX9, Per1, PHAPI2, Pinch-2, pki α, PLC γ2, POLA2, POLR2C, POLR2E, POLR2I, POLR2J3, PROCA1, Proliferation Marker, Protein tyrosine phosphatase receptor (PTPR), PTPκ, PXDNL, Rag D, RAG-1, RBMY1A1, RBP-L, ROPN1, ROR1, RP11-307F22.3, RPRC1, RSP3, SDR42E1, Sdt, Set1, Shank 3, Siglec-G, Siglec-H, Six5, SLA, SLA2, SLURP-2, SP140, Sp2, SPANX-A-E, SUSD4, TACI, TCL-6, TDF, Tec, TFIP11, TMC3, TNF receptor superfamily (TNFRSF), TRAAK, TRAF1, TRAP220, Trav12-2, Trav12d-1, Trav7-1, TRBV1, TRIL, TRIM43C, TRIQK, TTC33, TTYH1, UMPS, V1RC11, V1RD20, V1RE8, Vav, VHY, Vmn1r191, VpreB, VpreB1, VpreB2, VpreB3, WFIKKN2, YPEL, ZFOC1, ZNF12, ZNF254, ZNF439, ZNF547, ZNF548, ZNF684, and ZNHIT6.Activator of:
14-3-3 ζ, 2810008M24Rik, 2810011L19Rik, BCAP, BCMP1, Bcr, Bu-1a, CD300LG, CD38, CD72, DOCK 2, IBtk, IGLL5, MLLT11, and TACI.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ibrutinib, 10 mg | sc-483194 | 10 mg | $153.00 |